ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gabapentin

Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.

Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 28, 200744 company-led studies, 1 open or runningNext primary completion: Jan 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only201 open or runningphase 4since Sep 28, 2007Sep 8, 2005Jan 31, 2027phase 4 · NCT07813026
Depomedits history only80 open or runningphase 4since Jun 5, 2017Jun 8, 2006none ahead
Teva Pharmaceutical Industriesits history only60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Sun Pharmaceutical Industriesits history only40 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
GlaxoSmithKline20 open or runningphase 1since Sep 29, 2011Sep 29, 2011none ahead
Pharmaceutical Research Management srlits history only20 open or runningphase 3since Mar 18, 2016Mar 18, 2016none ahead
Nang Kuang Pharmaceuticalits history only10 open or runningphase 4since Feb 24, 2014Feb 24, 2014none ahead
Pfizerits history only10 open or runningphase 1since May 5, 2010May 5, 2010none ahead

Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2011First study: phase 1 study in NeuralgiaFirst studyNCT01485185 · 48 enrolled · United Kingdom
  2. Nov 28, 2012Phase 1 study in EpilepsyNCT01738893 · 26 enrolled

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149

Studies

All 2 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01738893Epilepsy1CompletedJan 22, 201126
NCT01485185Neuralgia · United Kingdom1CompletedJul 3, 201248

How it is read

Names in the registry

  • “Gabapentin”, 27 entries
  • “gabapentin”, 5 entries
  • “gabapentin 600 mg”, 3 entries
  • “Gabapentin Extended Release tablets”, 3 entries
  • “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.